FIGURE 7.

Overexpression of pyruvate dehydrogenase kinase 4 (PDK4) promotes proliferation and rituximab resistance in diffuse large B‐cell lymphoma cells. A, In vitro cell growth assay showing relative cell growth curves of OCI‐Ly8 empty vector (EV) and OCI‐Ly8 PDK4 overexpressing (OE) cells treated with rituximab (RTX, 50 μg/mL) for indicated times. B, OCI‐Ly8 EV and PDK4 OE cells were treated with RTX for 48 hours, and cell viability rates were analyzed using CCK‐8 assays. C, D, F, in vivo xenograft mouse models of OCI‐ly8 PDK4 OE or OCI‐ly8 EV cells treated with RTX (12.5 mg/kg) or PBS. Differences in tumor weight (D) and tumor volume (F) are shown between those four groups (n = 4). E, Body weight of mice in each experimental group measured at day 24. NS P > .05, *P < .05, **P < .01